Latest News

Guidelines highlight ‘best practices’ for liquid biopsy during treatment of non-small cell lung cancer

Fred R. Hirsch
Knowing how and when to use a liquid biopsy for molecular analysis of advanced non-small cell lung cancer is crucial to obtaining actionable information, according to a statement paper from International Association for the Study of Lung Cancer.
“Liquid biopsy and its subsequent molecular analysis is a powerful tool that can determine the patient’s molecular tumor profile in order to determine the best therapeutic option and can be applied as an alternative to tissue testing in cases where tumor testing is not possible or tissue is not adequate,” Fred R. Hirsch,

Related posts

Ology Bioservices Appoints Vaccines and Biologics Manufacturing Industry Veteran, Brandon Brega, as Chief Operating Officer


Mobile Clinics for Disaster Zones and Low Resource Communities: Interview with CEO of World Housing Solution


Research team identifies Ashkenazi Jewish founder mutation for Leigh syndrome


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy